These actions could postpone NIH-funded clinical trials and create cash flow issues for domestic biotech companies.

Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in ...

As an organization founded with an SBIR NIH/NCI grant to develop a patient-centric, AI-driven Deep Learning Clinical Trial ...

Brookline Capital Markets initiated coverage on Marker Therapeutics (NASDAQ:MRKR), a company focused on developing T cell-based immunotherapies for cancer, with a Buy rating and a 12-to-18-month price ...

University of Minnesota researchers and state lawmakers denounced Wednesday what they say are detrimental cuts to research facilities receiving National Institutes of Health funding announced last ...

She has been the Principal Investigator on multiple Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH) National Institute on Deafness and Other Communication ...

NIH announced it would limit indirect funding to 15% on Friday, but it is unclear how much money this will take from St. Jude ...

The National Institutes of Health (NIH) on Friday made a significant reduction in grants reserved for research institutions, a decision that may significantly impact American higher education.

“Without relief from NIH’s action, these institutions’ cutting-edge work to cure and treat human disease will grind to a halt.” The NIH is the primary source of federal funding for medical ...

Find out how it could impact their institutions and biomedical research nationwide. STORY HIGHLIGHTS: NIH cuts indirect costs to 15%, impacting Pitt and CMU. Universities warn of dire consequences ...

In an announcement issued by the NIH Office of the Director, the agency noted that it has historically supported indirect costs — administrative, facility, and other expenses not directly linked ...

Attorney General Andrea Campbell and 21 counterparts across the country sued the National Institutes of Health on Monday after the NIH said it would stop funding indirect costs for research.